New Study Links Psilocybin to Lower Risk of Opioid Addiction
Researchers attempt to replicate findings from a 2017 study that found classic psychedelic use conferred reduced risk of past-year opioid dependence and abuse.
Greg Gilman is Psychedelic Spotlight's lead content editor, as well as a contributor. His previous work has appeared in dozens of publications, including USA Today, Yahoo! News, TheWrap, MovieMaker Magazine and SyFy Wire. When he's not writing, he's the lead singer for LA-based Americana rock band Greg in Good Company. Given his experience as an artist, he's particularly interested in the intersection of psychedelics and entertainment.
Researchers attempt to replicate findings from a 2017 study that found classic psychedelic use conferred reduced risk of past-year opioid dependence and abuse.
This week in psychedelic business news: Field Trip Health secures a patent; Core One Labs seeks more retail investors; a new CEO takes over GABA Therapeutics.
The State acknowledges proposed psilocybin services rules will incur costs that “could ultimately be passed onto clients.”
This week in psychedelic business news: TripSitter expands; Enveric files a major patent; and Psychedelic Water raises its profile.
This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles.
This week in psychedelic business news: A psychedelics company folds; Ketamine Wellness Centers expand; Nova Mentis funds psilocybin studies.
The company was pursuing several psychedelic business strategies, including synthesizing ibogaine for researchers.
This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves a psilocybin PTSD study.
This week in psychedelic business news: Field Trip partners with Cerebral; Benzinga forms Psychedelic Advisory Council; Incannex pursues virtual reality psychedelic therapy.
Spoiler alert: It’s not because they’re depressed.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.